{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:36:26Z","timestamp":1792236986081,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1124\/dmd.124.001843","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T16:55:11Z","timestamp":1723049711000},"page":"1124-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans"],"prefix":"10.1016","volume":"52","author":[{"given":"Jonathan N.","family":"Bauman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Gualtieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Strelevitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-3809","authenticated-orcid":false,"given":"Matthew A.","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Plotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-6388","authenticated-orcid":false,"given":"Martin E.","family":"Dowty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.124.001843_bib1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1124\/dmd.122.000884","article-title":"Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach","volume":"50","author":"Doran","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001843_bib2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1124\/dmd.122.000883","article-title":"An Improved Method for Cytochrome P450 Reaction Phenotyping Using a Sequential Qualitative-Then-Quantitative Approach","volume":"50","author":"Doran","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001843_bib3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demostrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/dmd.124.001843_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.124.001843_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24 week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1124\/dmd.124.001843_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.116.072983","article-title":"Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms","volume":"45","author":"Leung","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001843_bib7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjp.0707251","article-title":"Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties","volume":"151","author":"Oettl","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.124.001843_bib8","unstructured":"Putnam FW. The Plasma Proteins, Volume IV, 2nd Edition, 1984."},{"key":"10.1124\/dmd.124.001843_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/psp4.12540","article-title":"Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study","volume":"9","author":"Spracklin","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.124.001843_bib10","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.124.001843_bib11","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.1021\/ac5015035","article-title":"Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range","volume":"86","author":"van Duijn","year":"2014","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.124.001843_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a Dual JAK3\/TEC Family Kinase Inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.124.001843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:56:28Z","timestamp":1740056188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624159119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0090955624159119"],"URL":"https:\/\/doi.org\/10.1124\/dmd.124.001843","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.124.001843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}